- 基本信息
导师姓名:
|
阎骅
|
学科代码:
|
100201
|
|
性别:
|
女
|
学科名称:
|
内科学
|
培养单位:
|
附属瑞金医院
|
三级学科
|
血液病
|
导师类型:
|
博士生导师
|
专业领域名称:
|
内科学 专业学位
|
联系方式:
|
|
专业领域代码:
|
105101
|
邮编:
|
|
邮箱地址:
|
yanhua_candy@163.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
|
中国临床肿瘤学会执行委员会委员
|
2013年获上海市中西医结合学会血液病专业委员会常务委员;
|
上海血液学分会青年委员会副主委
|
中国老年协会肿瘤协会青年委员
|
中国医师协会血液科医师分会多发性骨髓瘤专业委员会第一届委员会委员
|
中国老年学会血液会分会副理事长,常委
|
- 科研项目
81970192 | 剪切因子RBM39在多发性骨髓瘤中的病理机制研究 | 国家自然基金面上项目 |
2020-01~2023-12
|
55万元
| 课题负责人 |
81670198 | 低氧及骨髓基质细胞促多发性骨髓瘤耐药的作用及机制研 | 国家自然基金面上项目 |
2017-01~2020-12
|
57万元
| 课题负责人 |
16ZR1421400 | 土木香内酯抗慢性粒细胞白血病的机制研究 | 上海市自然科学基金资助项目 |
2016-07~2019-06
|
20万元
| 课题负责人 |
-- | 多发性骨髓瘤耐药相关lncRNAs 的功能鉴定及作用机制研究 | 上海高校化学生物学E研究院 |
2016-03~2018-12
|
30万元
| 课题负责人 |
81170509/h0812 | pharicin b稳定维甲酸受体的机制研究 | 国家自然基金面上项目 |
2012-01~2015-12
|
59万元
| 课题负责人 |
08431900700 | 慢性粒细胞白血病的治疗新策略及其机制研究 | 上海市科委生物医药重点科技攻关 |
2008-09~2011-09
|
30万元
| 课题负责人 |
30700334 | 蛋白酶体抑制剂联合砷剂诱导慢粒白血病细胞凋亡的深入研究 | 国家自然基金委,面上项目 |
2008-01~2010-12
|
17万元
| 课题负责人 |
2008AA02Z301 | 利用小分子化合物和RNAi研究抗白血病蛋白PLSCR1的作用网络 | 国家高技术研究发展计划 |
2008-01~2010-12
|
86万元
| 课题参与人 |
- 学术论文
Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y, Tong J, Li JM, Wu YL,
|
MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
|
Cell Death Dis.
|
2017
|
2017 May 11;8(5):e2776.
|
Yu W, Chen Y, Xiang R, Xu W, Wang Y, Tong J, Zhang N, Wu Y,
|
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
|
Leuk Lymphoma.
|
2017
|
2017 Feb;58(2):428-437.
|
Cao Y, Wei W, Zhang N, Yu Q, Xu WB, Yu WJ, Chen GQ, Wu YL,
|
Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-κB signaling.
|
BMC Cancer
|
2015
|
Apr 10;15:248
|
Wei W, Huang H, Zhao S, Liu W, Liu CX, Chen L, Li JM, Wu YL,
|
Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and BCR-ABL protein deletion
|
Apoptosis
|
2013
|
18(9) ,1060-70
|
Pozzi S, Fulciniti M,, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N.
|
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
|
Bone
|
2013
|
Apr;53(2):487-96
|
Huang H, Cao Y, Wei W, Liu W, Lu SY, Chen YB, Wang Y,, Wu YL.
|
Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.
|
Plos One
|
2013
|
Jun 7;8(6):e66130.
|
Shan Zhao, Chun-min Ma,Chuan-Xu Liu, Wei Wei, Yun Sun,, Ying-Li Wu
|
Autophagy inhibition enhances isobavachalcone-induced cell death in multiple myeloma cells
|
Internatioanl Jouranl of Molecular medicine
|
2012
|
30(4):939-44
|
, Wang YC, Li D, Wang Y, Wu YL, Chen GQ.
|
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemia cells: the role of protein kinase C?.
|
Leukemia
|
2007
|
21:1488-95
|
, Peng ZG, Wu YL, Jiang Y, Yu Y, Huang Y, Zhu YS, Zhao Q, Chen GQ.
|
Hypoxia-simulating agents and selectively stimulation of arsenic trioxide-induced cell growth arrest and differentiation in acute promyelocytic leukemic cells.
|
Hematologica
|
2005
|
90:1607-1616.
|
Huang Y, Du KM, Xue ZH,, Li D, Liu W, Chen Z, Zhao Q, Tong JH, Zhu YS, Chen GQ
|
Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha.
|
Leukemia
|
2003
|
17:2065–73.
|
Gu BW, Hu J, Xu L,, Jin WR, Zhu YM, Zhao WL, Niu C, Cao Q, Su XY, Gu J, Ying HY, Chen Y, Xiong SM, Shen ZX, Chen Z, Chen SJ.
|
Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RAR fusion transcript in patients with acute promyelocytic leukemia.
|
The Hematology Journal
|
2001
|
2: 330-340.
|
, Yan H(co-first author), Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ.
|
Studies on acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
|
Blood
|
1999
|
94:3315-3324
|
|